Genetic predictors of perioperative neurological and cognitive injury and recovery

Best Practice and Research: Clinical Anaesthesiology

Volumn 15, Issue 2, 2001, Pages 247-276

  Newman, Mark F ^a   Booth, John V ^a   Laskowitz, Daniel T ^a   Schwinn, Debra A ^a   Grocott, Hilary P ^a   Mathew, Joseph P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein E4; Cardiac surgery; Inflammation; Neurocognitive dysfunction; Stroke

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CATECHOLAMINE; FIBRINOGEN RECEPTOR; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGING; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CORONARY ARTERY BYPASS GRAFT; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; EMBOLISM; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEAD INJURY; HEART SURGERY; HUMAN; IMMUNOMODULATION; INCIDENCE; INFLAMMATION; METABOLIC REGULATION; NERVE INJURY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PERIOPERATIVE PERIOD; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATOR GENE; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0034902996     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1053/bean.2001.0155     Document Type: Article

References (138)

1. Changing efficacy of coronary revascularization: Implications for patients selection
2. Comparison of coronary artery bypass surgery and medical therapy in patients 65 years of age or older
3. Identification of patients at greatest risk for developing major complications at cardiac surgery
4. Coronary artery bypass grafting in the elderly: A review of studies on patients older than 64, 69, or 74 years
5. Primary myocardial revascularization
6. Coronary bypass surgery: Is the operation different today?
7. Cardiovascular morbidity and CABG surgery: A perspective: Epidemiology, costs, and potential solutions
8. Perioperative cardiac morbidity
9. The inflammatory cascade: A final common pathway for perioperative injury?
10. Stroke following coronary artery bypass grafting: A ten-year study
11. Differential effects of advanced age on neurologic and cardiac risks of coronary artery operations
12. Central nervous system complications for coronary artery bypass graft surgery: Prospective analysis of 421 patients
13. Neurologic complications of coronary artery bypass grafting: Case-control study neurology
14. Neurological complications of coronary revascularization
15. Stroke in the coronary bypass surgery
16. Cerebral complications of bypass surgery: A prospective study
17. Early neurological abnormalities following coronary artery bypass surgery. A prospective study
18. Cognitive and neurological function after coronary artery bypass surgery: A prospective study
19. Early neurological complications of coronary artery bypass surgery
20. Cerebral consequences of cardiopulmonary bypass
21. Neuropsychologic alterations after cardiac operation
22. Cerebral outcome after extracorporeal circulation: Comparison between prospective and retrospective evaluations
23. Improvement of outcomes after coronary artery bypass. A randomized trial comparing intraoperative high versus low mean arterial pressure
24. Adverse cerebral outcomes after coronary bypass surgery
25. A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery: (Part 2) neurological and cognitive outcomes
26. Long-term intellectual dysfunction following coronary artery bypass graft surgery: A six month follow-up study
27. Neurobehavioral outcomes in cardiac operations a prospective controlled study
28. Neuropsychological dysfunction following elective cardiac operation. II. A six-month reassessment
29. Neuropsychological sequelae of bypass twelve months after coronary artery surgery
30. Effects of nimodipine on cerebral blood flow and neuropsychological outcome after cardiac surgery
31. A randomized study of neuropsychological function in patients undergoing coronary bypass surgery
32. Pattern and time course of cognitive dysfunction following cardiopulmonary bypass
33. Long-term neurological and neuropsychological outcome 3 years after coronary artery bypass surgery
34. Residual cognitive dysfunction at 6 months following coronary artery bypass graft surgery
35. The persistence of neuropsychological deficits twelve months after coronary artery bypass surgery
36. Longitudinal assessment of neurocognitive function after coronary artery bypass surgery
37. Defining neuropsychological dysfunction after coronary artery bypass grafting
38. Impact of neurocognitive dysfunction on quality of life five years after cardiac surgery
39. Older patients have more emboli during coronary artery bypass graft surgery
40. Risk factors and solutions for the development of neurobehavioral changes after coronary artery bypass grafting
41. Microemboli during coronary artery bypass grafting. Genesis and effect on outcome
42. The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning
43. Cerebral emboli detected during bypass surgery are associated with clamp removal
44. Processing scavenged blood with a cell saver reduces cerebral lipid microembolization
45. Brain embolic phenomena associated with cardiopulmonary bypass
46. Atheromatous emboli: A cause of cerebral infarction
47. Spontaneous atheromatous embolization: Review of the literature and a report of 16 additional cases
48. Cerebral infarction by atheromatous emboli
49. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: Experience with intraoperative transesophageal echocardiography
50. The prevelance of atheromatous diseases of the ascending aorta and its relationship to such disease in the aortic arch
51. Aortic atheroma and the risk of stroke and encephalopathy after cardiac surgery
52. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty
53. Apolipoprotein E and Alzheimer disease
54. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathological Determinants of Atherosclerosis in Youth (PDAY) research group
55. Interleukin I: The first interleukin
56. Mechanical deformation promotes secretion of IL-1 alpha and IL-1 receptor antagonist
57. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta
58. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
59. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
60. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease
61. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
62. The natural history of systemic inflammatory response syndrome (SIRS). A prospective study
63. An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata
64. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist
65. Interleukin-1 receptor antagonist allele (ILIRN*2) associated with nephropathy in diabetes mellitus
66. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
67. Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway
68. The hemostatic system and coronary heart disease
69. Anticoagulant properties of the vascular endothelium
70. Platelets and coronary artery disease
71. Tailored therapy to fit individual profiles. Genetics and coronary artery disease
72. Genetic risk factors and restenosis after percutaneous coronary interventions
73. Activated protein C resistance - A major risk factor for thrombosis
74. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
75. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
76. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
77. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
78. Platelet glycoprotein IIb/IIIa receptors in cardivascular medicine
79. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
80. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study
81. Role of platelet glycoprotein PL(A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty
82. Prospective analysis after coronary-artery bypass grafting: Platelet GP IIIa polymorphism (HPA-I b/PlA2) is a risk factor for bypass occlusion, myocardial infarction, and death
83. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions
84. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese
85. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction
86. Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex
87. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine
88. Local effects of nitric oxide supplementation and suppression in the developments of intimal hyperplasia in experimental vein grafts
89. Enhanced in vivo platelet activation in subtypes of ischaemic stroke
90. Shear-induced platelet aggregation in normal subjects and stroke patients
91. A polymorphism of platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
92. PLA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
93. The Leu33/Pro polymorphism (PIA1/PIA2) of glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study
94. Polymorphism of platelet membrane glycoprotein IIIa: Human antigen Ib (HPA-Ib/PIA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease
95. Platelet GPIIIa PIA and GPIb variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke
96. 'Mini-mental state'. A practical method for grading the mental state of patients for the clinician
97. Prelilminary report of a genetic basis for cognitive decline after cardiac operations
98. A five-year longitudinal study of the mini-mental state examination in normal aging
99. Utility of PCR for DNA analysis from dried blood spots on filter paper blotters
100. Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers
101. Evolution of the functional human beta-actin gene and its multipseudogene family: Conservation of noncoding regions and chromosomal dispersion of pseudogenes
102. ApoE genotype and survival from intracerebral haemorrhage
103. Apolipoprotein E ε-4 allele is associated with deposition of amyloid β-protein following head injury
104. Association of apolipoprotein E polymorphism with outcome after head injury
105. ApoE as a prognostic factor for post-traumatic coma
106. Apolipoprotein E epsilon 4 associated with chronic traumatic brain injury in boxing
107. Apolioprotein E 4 and risk of dementia with stroke, a population based investigation
108. Stroke and apolipoprotein E epsilon 4 are independent risk factors for cognitive decline: A population-based study
109. Apolipoprotein E and the CNS response to injury
110. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transenic mice
111. The role of apoE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons
112. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production
113. Apolipoprotein E suppresses glial cell secretion of TNF alpha
114. ApoE genotype differentially influences the pro and anti-inflammatory response to cardiopulmonary bypass
115. Phenotypic effects of apolipoprotein structural variation on lipid profile. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the Healthy Women Study
116. Apolipoprotein E polymorphism and atherosclerosis
117. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site
118. Lipoprotein receptors and cholesterol homeostasis
119. Type III hyperlipoproteinemia: Defective metabolism of an abnormal apolipoprotein E
120. Apolipoprotein E metabolism in normolipoproteinemic human subjects
121. Abnormal in vivo metabolism of apolipoprotein E4 in humans
122. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B containing lipoproteins in humans
123. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study
124. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease
125. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women
126. Apolipoprotein E: A potent inhibitor of endothelial and tumor cell poliferation
127. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds
128. Apolipoprotein E secretion by macrophages: Its potential physiological functions
129. Apolipoprotein E4 increases atheroma burden in cardiac surgical patients
130. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation
131. Regional CBF in apolipoprotein E-deficient and wild type mice during focal cerebral ischemia
132. The platelet PIA2 polymorphism enhances the risk of neurocognitive decline after cardiopulmonary bypass
133. Apolipoprotein polymorphisms and age at first coronary artery bypass graft
134. Genetic predictors of perioperative neurologic and neuropsychological injury and recovery
135. Neuropsychometric deficit after cardiac surgery: A new approach for a new millennium
136. The role of apolipoprotein E ε4 in perioperative neurocognitive function in individuals undergoing coronary artery bypass surgery
137. Effect of apolipoprotein E genotype on cerebral heart autoregulation during cardiopulmonary bypass